Speaker illustration

Doctor Brian Halliday

National Heart and Lung Institute, London (United Kingdom of Great Britain & Northern Ireland)

Member of:

European Society of Cardiology

Brian Halliday is an Academic Clinical Lecturer at the National Heart and Lung Institute, based at the Cardiovascular Research Centre at the Royal Brompton Campus. He completed his undergraduate training at University of Edinburgh, before moving to London to continue his clinical training. In 2015, he started a PhD at the NHLI. This included the TRED-HF trial, which set out to examine the safety and feasibility of therapy withdrawal in patients deemed to have recovered dilated cardiomyopathy. He presented the results at the Late Breaking Clinical Trial Sessions at the American Heart Association, 2018 and was primary author of the simultaneous publication in The Lancet. He also investigated the use of CMR for the risk stratification of patients with dilated cardiomyopathy, focusing on improving the selection of patients for implantable cardioverter defibrillators. He has published articles in several high-impact journals on this topic.

Chronic heart failure - Elderly and frailty

Event: ESC Congress 2022

Topic: Chronic Heart Failure

Session type: Moderated ePosters

Thumbnail

Expect the unexpected on Acute Care cases

Event: ESC Acute CardioVascular Care 2022

Topic: Acute Coronary Syndromes

Session type: Clinical Cases

Thumbnail

Challenging cases on acute coronary syndromes

Event: ESC Acute CardioVascular Care 2022

Topic: Acute Coronary Syndromes

Session type: Clinical Cases

Thumbnail

Added value of CMR in nonischaemic heart disease

Event: EuroCMR 2021

Topic: Cardiac Magnetic Resonance (CMR)

Session type: Abstract Sessions

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb